OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.

Center for Outpatient Gynaecology and Primary Care Brno

Department of Obstetrics Gynecology and Neonatology General University Hospital 1 Medical Faculty Charles University Prague

G Center Olomouc

Institute of Biostatistics and Analyses Brno Czech Republic

Unilabs Pathology Prague

Zobrazit více v PubMed

Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, et al. . (2008). Screening- preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 100:622–629. PubMed

Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. . (2021). The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer 148:277–284. PubMed PMC

Canfell K. (2019). Towards the global elimination of cervical cancer. Papillomavirus Res 8:100170. PubMed PMC

Das M. (2021). WHO launches strategy to accelerate elimination of cervical cancer. Lancet Oncol 22:20–21. PubMed

Epidemiology and results of cervical cancer screening. Czech; 2022. https://www.cervix.cz/cs/lekari/epidemiologie-a-vysledky-screeningu/.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. . (2005). The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97:1072–1079. PubMed

Kjær SK, Frederiksen K, Munk C, Iftner T. (2010). Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102:1478–1488. PubMed PMC

Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. . (2005). Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 97:675–683. PubMed

McMenamin M, McKenna M, McDowell A. (2018). Clinical utility of cintec PLUS triage in equivocal cervical cytology and human papillomavirus primary screening. Am J Clin Pathol 150:512–521. PubMed

Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. . (2009). Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516–520. PubMed PMC

Obermair HM, Dodd RH, Bonner C, Jansen J, McCaffery K. (2018). ‘It has saved thousands of lives, so why change it?’ content analysis of objections to cervical screening programme changes in Australia. BMJ Open 8:e019171. PubMed PMC

Peterson EB, Ostroff JS, DuHamel KN, D’Agostino TA, Hernandez M, Canzona MR, et al. . (2016). Impact of provider-patient communication on cancer screening adherence: a systematic review. Prev Med 93:96–105. PubMed PMC

Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, et al. . (2011). Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki- 67 Dual-stained cytology. Gynecol Oncol 121:505–509. PubMed

Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. . (2012). Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13:78–88. PubMed

Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. .; International HPV screening working group (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:524–532. PubMed

Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, et al. . (2018). A report on the status of vaccination in Europe. Vaccine 36:4979–4992. PubMed

Wentzensen N, Schiffman M, Palmer T, Arbyn M. (2016). Triage of HPV positive women in cervical cancer screening. J Clin Virol 76(Suppl 1):S49–S55. PubMed PMC

Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. . (2019). Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Intern Med 179:881–888. PubMed PMC

Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. (2011). Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. preventive services task force. Ann Intern Med 155:687–97, W214-5. PubMed

Wilbur DC, Nayar R. (2015). Bethesda 2014: improving on a paradigm shift. Cytopathology 26:339–342. PubMed

Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. (2015). Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 136:189–197. PubMed

Wright TC, Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. . (2017). Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol 144:51–56. PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05578833